InvestSMART

Imugene Limited (ASX: IMU) - Announcements

- Current share price for IMU : $0.066

ASX company news and announcements for Imugene Limited (IMU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imugene Limited (IMU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imugene Limited (IMU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imugene Limited (IMU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$35 IMUGENE ANNOUNCES A$80 MILLION INSTITUTIONAL PLACEMENT 13 Sep 2022 8:54AM $0.225 $0.066 fallen by 70.67%
$35 Trading Halt 12 Sep 2022 9:04AM $0.225 $0.066 fallen by 70.67%
$35 Imugene doses first patient in nextHERIZON Phase 2 trial 8 Sep 2022 8:54AM $0.220 $0.066 fallen by 70%
$35 Application for quotation of securities - IMU 7 Sep 2022 5:32PM $0.220 $0.066 fallen by 70%
$35 Initial Director's Interest Notice - JD 7 Sep 2022 3:43PM $0.223 $0.066 fallen by 70.34%
$35 Imugene appoints Dr Jakob Dupont as Non-Executive Director 7 Sep 2022 9:53AM $0.220 $0.066 fallen by 70%
$35 Application for quotation of securities - IMU 2 Sep 2022 2:59PM $0.238 $0.066 fallen by 72.21%
$35 Release of Shares from Escrow 1 Sep 2022 1:02PM $0.255 $0.066 fallen by 74.12%
$35 Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA 1 Sep 2022 9:32AM $0.260 $0.066 fallen by 74.62%
$35 Environmental Social and Governance (ESG) Report 31 Aug 2022 8:18AM $0.240 $0.066 fallen by 72.50%
$35 Corporate Governance Statement 31 Aug 2022 8:11AM $0.240 $0.066 fallen by 72.50%
$35 Appendix 4G 31 Aug 2022 8:10AM $0.240 $0.066 fallen by 72.50%
$35 Annual Report and Appendix 4E 31 Aug 2022 8:09AM $0.240 $0.066 fallen by 72.50%
$35 FIRST COHORT 3 PATIENT DOSED IN CLINICAL TRIAL OF CHECKVACC 10 Aug 2022 9:18AM $0.270 $0.066 fallen by 75.56%
$35 Imugene Presents New PD1-Vaxx Data at the 2022 WCLC 8 Aug 2022 9:06AM $0.260 $0.066 fallen by 74.62%
$35 Application for quotation of securities - IMU 5 Aug 2022 4:32PM $0.260 $0.066 fallen by 74.62%
$35 Quarterly Activities/Appendix 4C Cash Flow Report 25 Jul 2022 11:27AM $0.240 $0.066 fallen by 72.50%
$35 Notification regarding unquoted securities - IMU 21 Jul 2022 4:48PM $0.250 $0.066 fallen by 73.60%
$35 Application for quotation of securities - IMU 21 Jul 2022 4:36PM $0.250 $0.066 fallen by 73.60%
$35 Imugene appoints experienced life sciences CFO Mike Tonroe 18 Jul 2022 9:35AM $0.250 $0.066 fallen by 73.60%
$35 IMU to Present New PD1-Vaxx Data at the WCLC 2022 13 Jul 2022 9:30AM $0.225 $0.066 fallen by 70.67%
$35 Appointment of Dr Sharon Yavrom as Clinical Scientist 1 Jul 2022 11:44AM $0.200 $0.066 fallen by 67%
$35 Investor Webinar - Final HER-Vaxx Overall Survival Results 27 Jun 2022 9:15AM $0.165 $0.066 fallen by 60%
$35 Final HER-Vaxx Phase 2 Trial Overall Survival Results 27 Jun 2022 8:24AM $0.165 $0.066 fallen by 60%
$35 Change of Director's Interest Notice - CW 14 Jun 2022 9:10AM $0.140 $0.066 fallen by 52.86%

426 - 450 of 1199 results

Page 18 of 48

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.